NASD · Consumer Defensive · Packaged Foods · USA
Niagen Bioscience Inc is a micro cap company (market value under $300 million) in the Packaged Foods industry.
Niagen Bioscience develops and sells nicotinamide riboside, a form of vitamin B3 that supports cellular NAD+ levels. The company operates through three business segments: consumer dietary supplements marketed as Tru Niagen® through online and retail channels across multiple countries; ingredient products supplied to manufacturers and pharmaceutical facilities; and analytical reference standards for quality control.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Niagen Bioscience Inc stock.
Undervalued: intrinsic value $3.29 per share, market price $2.04, margin of safety 38.0% (as of 2026-11-17).
Discounting its cash flows at 13.8% (average of 3 methods) values the shares at $3.29; the price of $2.04 is 38% below that value, and 63% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
6 more in this industry show a wider margin of safety.
NAGE is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 13.8% (average of 3 methods) values the shares at $3.29; the price of $2.04 is 38% below that value, and 63% of that value comes from beyond year five.
$3.29 per share (as of the 2026-11-17 close), against a market price of $2.04. That is a margin of safety of 38.0%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.